Evogene Q3 EPS $(0.08) Vs $(0.16) YoY, Sales $3.77M Beat $1.18M Estimate
Portfolio Pulse from Benzinga Newsdesk
Evogene (NASDAQ:EVGN) reported Q3 EPS of $(0.08), outperforming the consensus estimate of $(0.16) by 50%. Year-over-year, this marks an improvement from a loss of $(0.16) per share. Quarterly sales reached $3.77M, surpassing the $1.18M estimate by 219.24% and representing a 708.37% increase from the $466.00 thousand reported in the same period last year.
November 15, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evogene reported strong Q3 results with significant beats on both EPS and revenue estimates, indicating improved financial performance compared to the same period last year.
Evogene's better-than-expected earnings and substantial revenue growth are likely to be viewed positively by investors, potentially leading to a short-term increase in stock price. The substantial beat on both top and bottom lines suggests operational efficiency and growth, which are key drivers of investor sentiment.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100